RALEIGH, North Carolina, Jan. 10, 2026 (GLOBE NEWSWIRE) — Die Wachstumsstrategie von Attindas Hygiene Partners hat heute mit der Übernahme von Società Italiana Lavorazione Cellulosa (SILC S.p.A.) einen wichtigen [...] Read more »
Attindas Hygiene Partners renforce sa position en Europe grâce à une acquisition stratégique
RALEIGH, Caroline du Nord, 10 janv. 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners exécute aujourd’hui une étape majeure dans sa stratégie de croissance avec l’acquisition de Società [...] Read more »
Attindas Hygiene Partners Amplia Parceira na Europa com Importante Aquisição
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners dá um passo importante para sua estratégia de crescimento hoje com a aquisição da Societá Italiana [...] Read more »
Attindas Hygiene Partners Expands European Position with Key Acquisition
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners’ growth strategy realized an important step forward today with its acquisition of Societá Italiana Lavorazione Cellulosa (SILC [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3–Marburg Vaccine to Ethiopia to support the [...] Read more »
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
شركة Profound Medical توقع اتفاقية توزيع حصرية لمنتجات TULSA-PRO®وSonalleve® مع شركة Al Faisaliah Medical Systems في المملكة العربية السعودية
الاتفاقية تفتح المجال أمام علاجات [...] Read more »
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Agreement creates runway for Profound’s incision–free and radiation–free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East
Read more »
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical–stage biopharmaceutical company [...] Read more »
PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt
GOLDEN, Colo. and CAIRO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Read more »
Inteleos Opens Africa Office to Advance Basic Obstetric Point of Care Ultrasound (OPOCUS) Certification Across East Africa
ROCKVILLE, Md. and NAIROBI, Kenya, Oct. 30, 2025 (GLOBE NEWSWIRE) — Inteleos, a global nonprofit healthcare certification organization, expands its commitment to working on the ground in Africa to elevate the standard of global [...] Read more »
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two API [...] Read more »
Curia Investe US $4 Milhões para Aprimorar a Fabricação de APIs Estéreis
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), uma organização líder global em pesquisa, desenvolvimento e fabricação, anunciou hoje a conclusão de um investimento [...] Read more »
Curia investiert 4 Mio. US-Dollar in die Optimierung der Herstellung steriler Wirkstoffe
ALBANY, New York, Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), ein weltweit führendes Forschungs–, Entwicklungs– und Produktionsunternehmen, gab heute den Abschluss einer 4 Millionen US–Dollar [...] Read more »